Interview: Aurélien Chaufour – Managing Director, Anjac, France
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
Created in 2008, Anjac Health and Beauty consists of four experts and complementary companies in the areas of health, hygiene, beauty. Anjac is much more than a manufacturer who formulates, manufactures and packages products for companies in the areas of health, beauty and hygiene. Their added value is an ability to imagine and develop innovative customized solutions that make a difference to clients.
Today Anjac has four companies that are expert in the fields of health, hygiene and beauty. First, Shadeline, dynamic company specializing in dermatology and cosmetics. Second, Euro Wipes, a major player in the wipes market, offering a full range of wipes and impregnated cotton pads. Third, Sicaf, a well-established partner of luxury cosmetic brands, known for its expertise in formulation, manufacturing and custom packaging. And lastly, Chemineau, a European specialist in contract development and manufacturing of pharmaceutical products, cosmetics and medical devices. In total they have five manufacturing and R&D facilities. Each year more than a thousand formulations and five thousand products are conceived, manufactured and packaged in their five sites.
Contact
15, rue de la Banque,
75002, PARIS
T : +33 1 53 45 94 49
F : +33 1 53 45 94 59
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the…
Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and…
ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a…
At a time when France’s healthcare landscape is being reshaped by regulatory change, market pressure, and shifting patient expectations, Fabrice Ruggeri, Country Manager of Organon France, is steering the affiliate…
Under the leadership of Nicolas Bardonnet, Promega France has expanded its role from a broad portfolio provider to a more collaborative partner supporting key human health applications. Bardonnet has integrated…
Benta Lyon is reshaping its industrial footprint with unusual speed, combining a fast-growing CDMO platform, an expanding French made generics portfolio and new sterile capabilities that will anchor its next…
argenx has moved from an antibody engineering start-up to one of Europe’s most closely-watched biotechs, advancing a pipeline that spans multiple autoimmune diseases. In this interview, François Rauch reflects on…
With over 25 years of experience at the crossroads of science and business, Pascal Villemagne, CEO of SEQENS, shares his vision for steering the French CDMO into a new era…
France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and…
Jerome Estampes, CFO and interim CEO of Guerbet France, discusses his journey from joining the company in 2019 through to his current dual role, navigating the challenges of generic competition,…
Alexion France is entering a pivotal phase as the rare-disease landscape becomes more competitive, more data driven and increasingly shaped by early access and clinical-trial performance. In this interview, Celine…
See our Cookie Privacy Policy Here
